8-K: BD Announces CFO Transition, Preliminary Q4 & FY25 Revenue

Becton, Dickinson and Company announced its CFO's departure and provided preliminary unaudited revenue results for its fourth quarter and full fiscal year 2025.

Summary

• Christopher J. DelOrefice, Executive Vice President and Chief Financial Officer, will resign from his position effective December 5, 2025, to pursue a new professional opportunity.
• Vitor Roque, Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis, has been appointed interim Chief Financial Officer, effective upon Mr. DelOrefice's departure.
• Preliminary unaudited revenue for the fourth quarter fiscal 2025 was approximately $5.9 billion, representing an estimated increase of 8.3% on a reported basis, 7.0% currency-neutral, and 3.9% organic.
• Preliminary unaudited revenue for the full fiscal year 2025 was approximately $21.8 billion, representing an estimated increase of 8.2% on a reported basis, 7.7% adjusted currency-neutral, and 2.9% organic.
• The company expects to deliver full year fiscal 2025 adjusted diluted earnings per share (EPS) at or above the midpoint of its previously issued guidance.
• Mr. DelOrefice's departure is not the result of any disagreement with the company on matters relating to its financial statements, internal control over financial reporting, operations, policies, or practices.

Sentiment

Score: 6

Explanation: The filing presents a mixed but generally stable outlook. The CFO transition is a notable event, but it's framed as amicable with an experienced interim replacement, mitigating immediate concerns. Strong preliminary revenue growth and meeting/exceeding EPS guidance are positive. However, the acknowledgment of a 'greater than anticipated impact' from macro factors in specific segments introduces a degree of caution. The overall sentiment is cautiously optimistic, pending further details on the 'New BD strategy' and fiscal 2026 outlook.

Positives

• Strong revenue growth across multiple areas, including the BD Interventional segment, Advanced Patient Monitoring, and Medication Delivery Solutions.
• Full year fiscal 2025 adjusted diluted EPS is expected to be at or above the midpoint of previously issued guidance.
• The CFO's departure is not due to any disagreements regarding financial statements, internal controls, or company practices, indicating a smooth transition.
• Vitor Roque, the appointed interim CFO, brings over 20 years of extensive global finance and leadership experience within BD, ensuring continuity.

Negatives

• The company noted that a dynamic macro environment had a greater than anticipated impact in the fourth quarter, specifically affecting Pharmaceutical Systems vaccines and Biosciences academic and government research.
• The departure of the Executive Vice President and CFO creates a leadership transition period and necessitates a search for a permanent successor.

Risks

• Macroeconomic conditions and their impact on operations and healthcare spending, including disruptions in global transportation, supply chain, labor constraints, inflationary pressures, currency rate fluctuations, and increased interest rates.
• Conditions in international markets, including geopolitical developments in regions like Russia, Ukraine, the Middle East, and Asia.
• Competitive factors, including technological advances and new products or medical therapies introduced by competitors.
• Product efficacy or safety concerns, changes to labeled use of products, non-compliance with regulatory requirements (e.g., BD Alaris System, BD Vacutainer, BD Pyxis products), leading to recalls, lost revenue, or other actions.
• Changes to legislation or regulations impacting healthcare systems, changes in medical practices or patient preferences, potential cuts in governmental research or healthcare spending, or measures to contain healthcare costs (e.g., China's volume-based procurement).
• Policy and regulatory changes implemented by the U.S. federal government, including the elimination, downsizing, and reduced funding of certain agencies and programs.
• New or changing laws and regulations impacting the business, such as tariffs, sanctions, trade barriers, tax laws, environmental laws, cybersecurity, artificial intelligence, or privacy laws.
• Adverse impact on the business from past, current, or future information and technology system disruptions, breaches, or breakdowns, including cyberattacks.
• Increased labor costs and labor shortages or disputes.
• Suppliers' ability to provide necessary products and BD's ability to maintain favorable supplier arrangements.
• Increases in energy costs and their effect on product manufacturing.
• Adverse changes in regional, national, or foreign economic conditions, including impacts on access to credit markets.
• Risks relating to the company's overall indebtedness.
• The possible impact of public health crises on the business and the global healthcare system, potentially decreasing demand, disrupting operations, or increasing transportation costs.
• Interruptions in manufacturing or sterilization processes, including restrictions on the use of ethylene oxide.
• Pricing and market pressures.
• Difficulties inherent in product development, delays in product introductions, and uncertainty of market acceptance of new products.
• The overall timing of the replacement or remediation of the BD Alaris Infusion System and its return to market in the U.S.
• The ability to achieve projected level or mix of product sales.
• The ability to successfully integrate any businesses acquired.
• Uncertainties of litigation, investigations, subpoenas, settlements, fines, penalties, and/or other sanctions.
• The issuance of new or revised accounting standards.
• Risks associated with the proposed combination of BD's Biosciences and Diagnostic Solutions business with Waters, including the anticipated benefits and expected timing of completion.

Future Outlook

The company expects to deliver full year fiscal 2025 adjusted diluted earnings per share at or above the midpoint of its previously issued guidance. It plans to continue executing its strategy, taking further action to unlock value, including investments in growth opportunities and driving continued margin momentum. Further details on the 'New BD strategy' and expectations for fiscal 2026 will be shared on the upcoming earnings call.

Management Comments

• "Chris has been an important part of our Executive Leadership Team over the past four years as we delivered on our BD 2025 strategy and transformed our portfolio to lead in the evolving healthcare landscape." Tom Polen, Chairman, CEO and President of BD.
• "As we transition, Vitor brings extensive knowledge of the company having served in a broad range of finance leadership roles over his two decades at BD across our regions, business units and segments while also supporting key acquisitions. His strong finance and leadership capabilities position him well to serve as interim CFO as we continue to deliver on our strategic goals." Tom Polen.
• "While we continue to navigate a dynamic macro environment that had a greater than anticipated impact this quarter in areas we have been closely monitoring, specifically Pharmaceutical Systems vaccines and Biosciences academic and government research, we delivered strong growth across multiple areas including the BD Interventional segment, Advanced Patient Monitoring and Medication Delivery Solutions." Tom Polen.
• "Looking ahead, we continue to execute on our strategy and are taking further action to unlock value, including investments in areas of opportunity to drive growth and continued margin momentum. I look forward to sharing more on our New BD strategy and expectations for fiscal 2026 on our upcoming earnings call." Tom Polen.

Industry Context

The medical technology industry is currently navigating a complex macroeconomic environment, as evidenced by BD's acknowledgment of greater-than-anticipated impacts in specific segments like pharmaceutical systems vaccines and biosciences academic research. Despite these headwinds, the company's strong performance in areas such as interventional segments, advanced patient monitoring, and medication delivery solutions highlights the industry's ongoing innovation and demand in critical healthcare areas. Companies are adapting by strategically transforming their portfolios and investing in high-growth opportunities to maintain momentum.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Impacted by the CFO transition, preliminary financial results, and the company's future strategic direction. The positive EPS outlook is balanced by noted macro headwinds.
• Employees: The CFO transition affects the executive leadership team, with an internal appointment for the interim role.
• Customers: The company continues to focus on developing innovative technology, services, and solutions to advance healthcare.
• Investment Professionals: Provided with key preliminary financial data and insights into management changes and strategic priorities, aiding in their analysis and recommendations.

Next Steps

• Conduct a search to identify a permanent Chief Financial Officer.
• Host an audio webcast on November 6, 2025, to discuss financial results for the fourth quarter and full year fiscal 2025.
• Issue a news release and related presentation materials prior to the webcast.
• Continue to execute on strategy and take further action to unlock value, including investments in areas of opportunity to drive growth and continued margin momentum.
• Share more on the 'New BD strategy' and expectations for fiscal 2026 on the upcoming earnings call.

Key Dates

Recommendation

The company is navigating a significant leadership transition with the CFO's departure, which, while amicable, introduces a period of uncertainty until a permanent successor is named. Although preliminary revenue growth is strong and EPS guidance is met or exceeded, management acknowledged a 'greater than anticipated impact' from macro headwinds in specific segments. The appointment of an experienced interim CFO provides stability, but investors will likely await the permanent CFO appointment and further details on the 'New BD strategy' and fiscal 2026 outlook before making significant investment decisions. The current situation warrants a 'hold' stance, favoring observation over aggressive buying or selling.

Keywords

Becton Dickinson, BDX, CFO, Chief Financial Officer, Revenue, Financial Results, Q4 2025, Fiscal Year 2025, Medical Technology, Healthcare, Earnings Per Share, Management Change, Interim CFO, Preliminary Results